

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fusen Pharmaceutical Company Limited

福森藥業有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1652)

**(1) DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS
ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2019;
(2) PUBLICATION OF UNAUDITED ANNUAL RESULTS
ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2019;
AND
(3) DATE OF BOARD MEETING**

**DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS ANNOUNCEMENT
FOR THE YEAR ENDED 31 DECEMBER 2019**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Fusen Pharmaceutical Company Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) announces that, due to the novel coronavirus outbreak in January 2020, the auditing processes of the financial results of the Group for the year ended 31 December 2019 have not yet been completed as the Company’s auditors, KPMG, have not been able to arrange their staff to travel to Henan, Mainland China to perform audit fieldwork since February 2020 due to the quarantine requirements imposed by the People’s Government of Henan Province amid the novel coronavirus outbreak.

Given that the auditing processes have not yet been completed, the Company is not able to publish the audited annual results announcement of the Group for the year ended 31 December 2019 in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

As at the date of this announcement, the Directors are not able to determine the expected date of announcement of the audited annual results of the Group for the year ended 31 December 2019 which shall have been agreed with KPMG as KPMG are not able to determine the timetable for arranging their staff to travel to Henan, Mainland China to perform audit fieldwork due to the quarantine requirements that continue in force for preventing more imported cases of the novel coronavirus.

PUBLICATION OF UNAUDITED ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2019

To minimise disruptions to trading of the Company's shares while ensuring that the shareholders of the Company and investing public continue to receive sufficient information to make informed investment decisions, the Directors have decided to publish the unaudited annual results announcement of the Group for the year ended 31 December 2019 on 31 March 2020.

DATE OF BOARD MEETING

The Directors announce that, a meeting of the Board will be held on Tuesday, 31 March 2020 for the purpose of, among other matters, approving the unaudited annual results of the Group for the year ended 31 December 2019 and considering the payment of a final dividend, if any.

By order of the Board
Fusen Pharmaceutical Company Limited
Cao Changcheng
Chairman and Executive Director

Hong Kong, 19 March 2020

As at the date of this announcement, the Board of the Company comprises Mr. Cao Changcheng (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng, Ms. Meng Qingfen and Mr. Cao Zhiming as executive Directors, and Mr. Sze Wing Chun, Mr. Ho Ka Chun and Mr. Lee Kwok Tung, Louis as independent non-executive Directors.